Table 3.
Variables | Remission at month-12 (n=41) | No remission at month-12 (n=27) | Univariate P-value | Multivariate P-value |
---|---|---|---|---|
Age (years) | 60.0 [50.0–68.0] | 56.0 [42.0–67.0] | 0.3 | |
Gender (Female/Male) | 11/30 | 8/19 | 1 | |
Weight (kg) at baseline* | 71.5 [66.0–82.0] | 78.0 [74.0–89.2] | 0.06 | 0.02 |
UP (g/d) at baseline* | 5.2 [4.0–7.1] | 7.4 [5.6–11.9] | 0.005 | 0.2 |
Serum creatinine (µmol/L) at baseline | 118 [87–149] | 123 [87–184] | 0.4 | |
Serum albumin (g/L) at baseline* | 24.8 [20.2–29.4] | 16.0 [13.0–22.1] | 0.001 | 0.7 |
CD19+ count (cell/µL) at baseline | 186.0 [125.0–285.0] | 185.0 [88.7–263.8] | 0.9 | |
CD19+ count (cell/µL) at month-3* | 0.0 [0.0–2.7] | 3.0 [1.0–16.0] | 0.005 | 0.9 |
Etiology | 0.8 | |||
Anti-PLA2R1-associated pMN | 37 (90%) | 25 (93%) | ||
Anti-THSD7A-associated pMN | 1 (2%) | 1 (3%) | ||
Double negative patients | 3 (8%) | 1 (3%) | ||
Anti-PLA2R1 Ab titer (RU/mL) at baseline* | 86 [21–188] | 226 [110–561] | 0.001 | 0.5 |
Patient with RTX <2µg/mL at month-3* | 16 (26%) | 22 (85%) | 0.001 | 0.01 |
*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.
Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.